Table 2.
Tumor characteristics
| Variable | Age < 75 | Age 75 + | Overall | p-value |
|---|---|---|---|---|
| Number of patients | 979 | 156 | 1135 | |
|
| ||||
| Pathologic tumor sizea | 0.159 | |||
| Mean (SD) | 3.43 (2.23) | 3.72 (2.27) | 3.47 (2.24) | |
| Median (IQR) | 3.00 (2.50) | 3.10 (2.80) | 3.00 (2.50) | |
| Histologyb | 0.671 | |||
| Adenocarcinoma | 835 (85.55%) | 130 (83.33%) | 965 (85.25%) | |
| Squamous cell carcinoma | 129 (13.22%) | 23 (14.74%) | 152 (13.43%) | |
| Other | 12 (1.23%) | 3 (1.92%) | 15 (1.33%) | |
| Histologic gradec | 0.174 | |||
| 1 | 63 (6.58%) | 5 (3.27%) | 68 (6.13%) | |
| 2 | 324 (33.86%) | 63 (41.18%) | 387 (34.86%) | |
| 3 | 429 (44.83%) | 66 (43.14%) | 495 (44.59%) | |
| Not defined | 141 (14.73%) | 19 (12.42%) | 160 (14.41%) | |
| Positive margin | ||||
| Overall | 32 (3.27%) | 7 (4.49%) | 39 (3.44%) | 0.59 |
| Radiald | 24 (2.48%) | 4 (2.65%) | 28 (2.50%) | > 0.999 |
| Longitudinal | 9 (0.92%) | 4 (2.56%) | 13 (1.15%) | 0.165 |
| Lymph node count | ||||
| Median (IQR) | 18.00 (9.00) | 19.00 (10.00) | 18.00 (9.00) | 0.293 |
| Positive lymph node count | ||||
| Median (IQR) | 0.00 (1.00) | 0.00 (1.00) | 0.00 (1.00) | 0.542 |
| Lymphovascular invasion present | 179 (18.28%) | 40 (25.64%) | 219 (19.30%) | 0.04 |
| Venous invasion presente | 33 (3.54%) | 8 (5.44%) | 41 (3.80%) | 0.374 |
| Perineural invasion present | 162 (16.55%) | 28 (17.95%) | 190 (16.74%) | 0.749 |
| Tumor location inf esophagus | 0.007 | |||
| Upper/proximal | 9 (0.92%) | 6 (3.85%) | 15 (1.32%) | |
| Middle | 100 (10.24%) | 20 (12.82%) | 120 (10.59%) | |
| Distal/gastroesophageal junction | 868 (88.84%) | 130 (83.33%) | 998 (88.08%) | |
| Clinical T stage | 0.499 | |||
| T0/is | 3 (0.31%) | 0 (0.00%) | 3 (0.26%) | |
| 1 | 121 (12.36%) | 18 (11.54%) | 139 (12.25%) | |
| 2 | 191 (19.51%) | 38 (24.36%) | 229 (20.18%) | |
| 3 | 484 (49.44%) | 68 (43.59%) | 552 (48.63%) | |
| 4 | 14 1.43%) | 1 (0.64%) | 15 (1.32%) | |
| Not defined/missing | 166 (16.96%) | 31 (19.87%) | 197 (17.36%) | |
| Clinical N stage | 0.153 | |||
| 0 | 374 (38.20%) | 68 (43.59%) | 442 (38.94%) | |
| 1 | 385 (39.33%) | 47 (30.13%) | 432 (38.06%) | |
| 2 | 82 (8.38%) | 11 (7.05%) | 93 (8.19%) | |
| 3 | 5 (0.51%) | 1 (0.64%) | 6 (0.53%) | |
| Not defined/missing | 133 (13.59%) | 29 (18.59%) | 162 (14.27%) | |
| Clinical M stage | 0.187 | |||
| 0 | 14 (0.43%) | 5 (3.21%) | 19 (1.67%) | |
| 1 | 5 (0.51%) | 0 (0.00%) | 5 (0.44%) | |
| Not defined/missing | 960 (98.06%) | 151 (96.79%) | 1111 (97.89%) | |
| Clinical TNM stage | 0.843 | |||
| 1 | 100 (11.79%) | 16 (12.60%) | 116 (11.90%) | |
| 2 | 196 (23.11%) | 33 (25.98%) | 229 (23.49%) | |
| 3 | 472 (55.66%) | 68 (53.54%) | 540 (55.38%) | |
| 4 | 80 (9.43%) | 10 (7.87%) | 90 (9.23%) | |
| Missing | 131 | 29 | 160 | |
| Pathologic T stage | 0.77 | |||
| 0 | 246 (25.13%) | 34 (21.79%) | 280 (24.67%) | |
| Is | 1 (0.10%) | 0 (0.00%) | 1 (0.09%) | |
| 1 | 242 (24.72%) | 36 (23.08%) | 278 (24.49%) | |
| 2 | 154 (15.73%) | 30 (19.23%) | 184 (16.21%) | |
| 3 | 319 (32.58%) | 53 (33.97%) | 372 (32.78%) | |
| 4 | 12 (1.23%) | 3 (1.92%) | 15 (1.32%) | |
| Not defined/missing | 5 (0.51%) | 0 (0.00%) | 5 (0.44%) | |
| Pathologic N stage | 0.893 | |||
| 0 | 666 (68.03%) | 104 (66.67%) | 770 (67.84%) | |
| 1 | 173 (17.67%) | 29 (18.59%) | 202 (17.80%) | |
| 2 | 95 (9.70%) | 17 (10.90%) | 112 (9.87%) | |
| 3 | 40 (4.09%) | 6 (3.85%) | 46 (4.05%) | |
| Not defined/missing | 5 (0.51%) | 0 (0.00%) | 5 (0.44%) | |
| Pathologic M stage | 0.957 | |||
| 0 | 849 (86.72%) | 134 (85.90%) | 983 (86.61%) | |
| 1 | 11 (1.12%) | 2 (1.28%) | 13 (1.15%) | |
| Not defined/missing | 119 (12.16%) | 20 (12.82%) | 139 (12.25%) | |
| Pathologic TNM stage | 0.928 | |||
| 1 | 534 (54.71%) | 82 (52.56%) | 616 (54.42%) | |
| 2 | 123 (12.60%) | 22 (14.10%) | 145 (12.81%) | |
| 3 | 269 (27.56%) | 43 (27.56%) | 312 (27.56%) | |
| 4 | 50 (5.12%) | 9 (5.77%) | 59 (5.21%) | |
| Missing | 3 | 0 | 3 | |
| HER 2 status | 0.7 | |||
| Negative | 152 (15.53%) | 21 (13.46%) | 173 (15.24%) | |
| Positive | 32 (3.27%) | 4 (2.56%) | 36 (3.17%) | |
| Not reported | 795 (81.21%) | 131 (83.97%) | 926 (81.59%) | |
| Signet cell histology present on biopsy or final pathology | 142 (14.50%) | 13 (8.33%) | 155 (13.66%) | 0.05 |
IQR interquartile range, SD standard deviation, TNM tumor, node, metastases
a
Reported out of n = 978
b
Reported out of n = 1132
c
Reported out of n = 1110
d
Reported out of n = 1118
e
Reported out of n = 1079
f
Reported out of n = 1133